SAN DIEGO—Just over a year after approval, AstraZenca’s Calquence is giving Johnson & Johnson and AbbVie’s Imbruvica a run for its money in mantle cell lymphoma. But the British drugmaker doesn’t want ...
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca’s CALQUENCE ® (acalabrutinib) in combination with ...
WILMINGTON, Del.--(BUSINESS WIRE)-- Positive results from the ECHO Phase III trial showed AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab demonstrated a ...
WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s supplemental New Drug Application (sNDA) for CALQUENCE® (acalabrutinib) has been accepted and granted Priority Review in the US for the treatment of ...
There was no major difference in progression-free survival between patients with relapsed/refractory chronic lymphocytic leukemia who were treated with Calquence or Brukinsa. Patients treated with ...
Fewer patients with chronic lymphocytic leukemia experienced cardiac toxicities with Calquence than those treated with Imbruvica, research showed. Calquence (acalabrutinib) led to fewer ...
Chronic lymphocytic leukemia (CLL), is a type of cancer that affects a type of white blood cell in your body called a lymphocyte. White blood cells are made in your bone marrow and help your body ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results